Product mentioned on podcasts
Atabimetinib
by Immuneering
Mentioned on 1 episode by 1 guest across our covered podcasts.
SignalCast may earn commission on purchases via these links.
Who mentioned it
- Ben ZeskinAuthor
“Immuneering CEO Ben Zeskind explains how the company's informatics-driven "deep cyclic inhibition" approach to MEK inhibition delivers intense daily pulses... Atabimetinib is novel composition-of-matter, with a US patent granted in summer 2024”
Mentioned on: The Bio Report